Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Dec;13(4):811-814.
doi: 10.1007/s40119-024-00382-5. Epub 2024 Oct 23.

Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'

Arnt V Kristen  1   2   3 , Carsten Tschöpe  4   5 , Stephanie Schwarting  6   5   7 , Fabian Aus dem Siepen  6   5
Affiliations
Comment

Letter to the Editor Regarding 'Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)'

Arnt V Kristen et al. Cardiol Ther. 2024 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Arnt V. Kristen is an advisor to Pfizer Pharma GmbH and has received speaker fees. Carsten Tschöpe is an advisor to Pfizer Pharma GmbH and has received speaker fees. Stephanie Schwarting is an advisor to Pfizer Pharma GmbH and has received speaker fees. Fabian aus dem Siepen is an advisor to Pfizer Pharma GmbH and has received speaker fees. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Attal S, Kemner J, Alvir J, Barth S, Schuessler S. 61 mg patient characteristics and persistency? A retrospective analysis of German Statutory Health Insurance Data (IQVIA™ LRx). Cardiol Ther. 2024. 10.1007/s40119-024-00365-6. - PMC - PubMed
    1. Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024;402:131813. 10.1016/j.ijcard.2024.131813. - PubMed
    1. Emdin M, Aimo A, Vergaro G, Castiglione V. Beta-blocking patients with cardiac amyloidosis: adelante cum juicio. Int J Cardiol. 2024;407:132039. 10.1016/j.ijcard.2024.132039. - PubMed
    1. Aus dem Siepen F, Hein S, Hofmann E, Nagel C, Schwarting SK, Hegenbart U, Schönland SO, Weiler M, Frey N, Kristen AV. Prognostic value of standard heart failure medication in patients with cardiac transthyretin amyloidosis. J Clin Med. 2024;13(8):2257. - PMC - PubMed
    1. Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid. 2017;24(1):132–3. - PubMed

LinkOut - more resources